These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 12706930)

  • 1. Myocardial viability in chronic ischemic heart disease: comparison of contrast-enhanced magnetic resonance imaging with (18)F-fluorodeoxyglucose positron emission tomography.
    Kühl HP; Beek AM; van der Weerdt AP; Hofman MB; Visser CA; Lammertsma AA; Heussen N; Visser FC; van Rossum AC
    J Am Coll Cardiol; 2003 Apr; 41(8):1341-8. PubMed ID: 12706930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging and comparison with single-photon emission computed tomography.
    Wang YN; Jin ZY; Zhang ZH; Kong LY; Chen LB; Zhou L; Sun HY; Zhang H; Miao Q
    Chin Med Sci J; 2006 Dec; 21(4):239-44. PubMed ID: 17249199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography for the assessment of myocardial viability: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(16):1-80. PubMed ID: 23074393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of contrast-enhanced MRI with (18)F-FDG PET/201Tl SPECT in dysfunctional myocardium: relation to early functional outcome after surgical revascularization in chronic ischemic heart disease.
    Wu YW; Tadamura E; Yamamuro M; Kanao S; Marui A; Tanabara K; Komeda M; Togashi K
    J Nucl Med; 2007 Jul; 48(7):1096-103. PubMed ID: 17607039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positron emission tomography for the assessment of myocardial viability: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(16):1-167. PubMed ID: 23074467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance imaging (MRI) for the assessment of myocardial viability: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(15):1-45. PubMed ID: 23074392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline/post-nitrate Tc-99m tetrofosmin mismatch for the assessment of myocardial viability in patients with severe left ventricular dysfunction: comparison with baseline Tc-99m tetrofosmin scintigraphy/FDG PET imaging.
    Giorgetti A; Marzullo P; Sambuceti G; Di Quirico S; Kusch A; Landi P; Salvadori PA; Pisani P; L'abbate A
    J Nucl Cardiol; 2004; 11(2):142-51. PubMed ID: 15052245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myocardial viability in chronic ischemic heart disease: comparison of delayed-enhancement magnetic resonance imaging with 99mTc-sestamibi and 18F-fluorodeoxyglucose single-photon emission computed tomography.
    Liu Q; Zhao S; Yan C; Lu M; Jiang S; Zhang Y; Li S; Liu Y; Yang M; He Z
    Nucl Med Commun; 2009 Aug; 30(8):610-6. PubMed ID: 19491715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agreement and disagreement between contrast-enhanced magnetic resonance imaging and nuclear imaging for assessment of myocardial viability.
    Roes SD; Kaandorp TA; Marsan NA; Westenberg JJ; Dibbets-Schneider P; Stokkel MP; Lamb HJ; van der Wall EE; de Roos A; Bax JJ
    Eur J Nucl Med Mol Imaging; 2009 Apr; 36(4):594-601. PubMed ID: 19050879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tc-99m tetrofosmin tomography after nitrate administration in patients with ischemic left ventricular dysfunction: relation to metabolic imaging by PET.
    He W; Acampa W; Mainolfi C; Menna F; Sorrentino AR; Petretta M; Cuocolo A
    J Nucl Cardiol; 2003; 10(6):599-606. PubMed ID: 14668771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline/postnitrate tetrofosmin SPECT for myocardial viability assessment in patients with postischemic severe left ventricular dysfunction: new evidence from MRI.
    Giorgetti A; Pingitore A; Favilli B; Kusch A; Lombardi M; Marzullo P
    J Nucl Med; 2005 Aug; 46(8):1285-93. PubMed ID: 16085584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of reversible myocardial dysfunction in chronic ischaemic heart disease: comparison of contrast-enhanced cardiovascular magnetic resonance and a combined positron emission tomography-single photon emission computed tomography imaging protocol.
    Kühl HP; Lipke CS; Krombach GA; Katoh M; Battenberg TF; Nowak B; Heussen N; Buecker A; Schaefer WM
    Eur Heart J; 2006 Apr; 27(7):846-53. PubMed ID: 16434414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of myocardial viability with contrast-enhanced magnetic resonance imaging--comparison of the late enhancement technique with positronemission tomography].
    Hunold P; Brandt-Mainz K; Freudenberg L; Vogt FM; Neumann T; Knipp S; Barkhausen J
    Rofo; 2002 Jul; 174(7):867-73. PubMed ID: 12101477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of low-dose dobutamine-gradient-echo magnetic resonance imaging and positron emission tomography with [18F]fluorodeoxyglucose in patients with chronic coronary artery disease. A functional and morphological approach to the detection of residual myocardial viability.
    Baer FM; Voth E; Schneider CA; Theissen P; Schicha H; Sechtem U
    Circulation; 1995 Feb; 91(4):1006-15. PubMed ID: 7850935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuation-corrected 99mTc-tetrofosmin single-photon emission computed tomography in the detection of viable myocardium: comparison with positron emission tomography using 18F-fluorodeoxyglucose.
    Matsunari I; Böning G; Ziegler SI; Nekolla SG; Stollfuss JC; Kosa I; Ficaro EP; Schwaiger M
    J Am Coll Cardiol; 1998 Oct; 32(4):927-35. PubMed ID: 9768713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of viable myocardium in patients with chronic coronary artery disease and left ventricular dysfunction. Comparison of thallium scintigraphy with reinjection and PET imaging with 18F-fluorodeoxyglucose.
    Bonow RO; Dilsizian V; Cuocolo A; Bacharach SL
    Circulation; 1991 Jan; 83(1):26-37. PubMed ID: 1984883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dobutamine stress echocardiography and technetium-99m-tetrofosmin/fluorine 18-fluorodeoxyglucose single-photon emission computed tomography and influence of resting ejection fraction to assess myocardial viability in patients with severe left ventricular dysfunction and healed myocardial infarction.
    Rambaldi R; Poldermans D; Bax JJ; Boersma E; Valkema R; Elhendy A; Vletter WB; Fioretti PM; Roelandt JR; Krenning EP
    Am J Cardiol; 1999 Jul; 84(2):130-4. PubMed ID: 10426327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of diabetes mellitus on prediction of clinical outcome after coronary revascularization by 18F-FDG SPECT in patients with ischemic left ventricular dysfunction.
    Schinkel AF; Poldermans D; Rizzello V; van Domburg RT; Valkema R; Elhendy A; Biagini E; Krenning EP; Simoons ML; Bax JJ
    J Nucl Med; 2006 Jan; 47(1):68-73. PubMed ID: 16391189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of nitrate augmented Tc-99m tetrofosmin gated SPECT imaging with FDG PET imaging for the assessment of myocardial viability in patients with severe left ventricular dysfunction.
    Raja S; Singh B; Rohit MK; Manohar K; Kashyap R; Bhattacharya A; Mittal BR
    J Nucl Cardiol; 2012 Dec; 19(6):1176-81. PubMed ID: 22872319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective Evaluation of 18F-Fluorodeoxyglucose Uptake in Postischemic Myocardium by Simultaneous Positron Emission Tomography/Magnetic Resonance Imaging as a Prognostic Marker of Functional Outcome.
    Rischpler C; Dirschinger RJ; Nekolla SG; Kossmann H; Nicolosi S; Hanus F; van Marwick S; Kunze KP; Meinicke A; Götze K; Kastrati A; Langwieser N; Ibrahim T; Nahrendorf M; Schwaiger M; Laugwitz KL
    Circ Cardiovasc Imaging; 2016 Apr; 9(4):e004316. PubMed ID: 27056601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.